Compare YARW & LANV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YARW | LANV |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.6M | 115.8M |
| IPO Year | 2017 | 2022 |
| Metric | YARW | LANV |
|---|---|---|
| Price | $18.90 | $0.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $57.00 | N/A |
| AVG Volume (30 Days) | ★ 95.8K | 16.8K |
| Earning Date | 11-03-2026 | 08-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.24 | $0.85 |
| 52 Week High | $44.28 | $2.31 |
| Indicator | YARW | LANV |
|---|---|---|
| Relative Strength Index (RSI) | 32.49 | 32.21 |
| Support Level | $18.24 | N/A |
| Resistance Level | $32.89 | $1.13 |
| Average True Range (ATR) | 1.95 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 13.55 | 0.00 |
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the St. John segment.